http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101132439-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-551 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-551 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2004-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101132439-B1 |
| titleOfInvention | Evaluation of Adjuvant-Added Vaccines |
| abstract | The present invention relates to a method for assessing the immunological activity of a vaccine formulation in the form of a mixture of antigen molecules and mediators, wherein the mixture comprises a solid phase and a liquid phase to which at least a portion of the antigen is attached.n n n Iii) the vaccine is subjected to one or more measurements selected from the following groups:n n n 1) immunological activity of the mixture,n n n 2) immunological activity of antigens in the liquid phase,n n n 3) immunological activity of the antigen in the solid phase,n n n 4) immunological activity of the antigen in the liquid phase upon treatment of the mixture to replace the antigen from the solid phase, andn n n 5) immunological activity of the antigen in the solid phase upon treatment of the mixture for substituting the antigen from the solid phase,n n n Wherein the measurement of immunological activity includes a) the ability of antibody binding using an immunoassay using an antigen-specific antibody bound to the antibody solid phase, b) the ability to activate effector cells, and c) the potential for induction of anaphylaxis; Selected from the group consisting of; Andn n n Ii) using the measurement results to assess the immunological activity of the vaccine.n n n n Immunological activity, vaccines, allergens |
| priorityDate | 2003-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 575.